Vertex Pharmaceuticals Inc annual free cash flow for fiscal TTM was $3.7 billion, an increase of 16.2% from $3.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $3.7B | $3.2B | ($790M) | $3.3B | $3.9B | $2.4B | $3.0B | $1.5B | $1.2B | $586M | $180M | ($411M) | ($564M) | ($103M) | $197M | $49M | ($673M) | ($451M) | ($259M) | ($285M) | ($55M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $1.3B | $349M | $1.1B | $927M | $778M | $492M | $1.3B | ($3.8B) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More VRTX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All VRTX financial statements → Interactive VRTX charts →
About TickerBase · Data methodology & sources